modelA07EC02_1
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Mesalazine_1 | |
| ATC code: | A07EC02_1 | route: | oral |
| compartments: | 1 | |
| dosage: | 2400 | mg |
| volume of distribution: | 8.3 | L |
| clearance: | 4.4 | L/h |
| other parameters in model implementation | ||
Mesalazine (also known as mesalamine or 5-aminosalicylic acid) is an anti-inflammatory drug used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. It is approved and widely used today, primarily for induction and maintenance of remission in these conditions.
Pharmacokinetics
Population pharmacokinetic estimates for patients with inflammatory bowel disease taking oral delayed-release mesalazine tablets.
References
Zhang, Y, et al., & Zuo, Z (2022). Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets. Journal of controlled release : official journal of the Controlled Release Society 346 275–288. DOI:10.1016/j.jconrel.2022.04.024 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35461968
Lück, H, et al., & Sörgel, F (2009). Mesalazine pharmacokinetics and NAT2 phenotype. European journal of clinical pharmacology 65(1) 47–54. DOI:10.1007/s00228-008-0550-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18704388
Wiersma, H, et al., & Taminiau, J (2004). Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflammatory bowel diseases 10(5) 626–631. DOI:10.1097/00054725-200409000-00019 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15472525
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)